{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["104(3)"],"submitter":["Costa LJ"],"funding":["Amgen"],"pubmed_abstract":["Although survival rates for patients with newly diagnosed multiple myeloma (NDMM) have improved over recent decades, multiple myeloma (MM) remains without a cure for most. There is increasing consensus that achievement of deep remissions, especially minimal residual disease negativity (MRD -), in frontline treatment is crucial and translates into improved survival. The standard of care (SOC) for NDMM consists at minimum of a triplet regimen of therapies, with or without an autologous stem cell transplant, or a doublet regimen for certain ineligible, particularly frail patients who may have specific limitations. Recently, anti-CD38 monoclonal antibodies (mAbs), such as daratumumab (Dara) or isatuximab (Isa), have been integrated into frontline SOC regimens. Seeking to further deepen and pro"],"journal":["Annals of hematology"],"pagination":["1329-1351"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12031813"],"repository":["biostudies-literature"],"pubmed_title":["Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies."],"pmcid":["PMC12031813"],"pubmed_authors":["Touzeau C","McFadden I","Gay F","Costa LJ","Mateos MV","Weisel K","Moreau P","Landgren O","Ertel F","Najdi R"],"additional_accession":[]},"is_claimable":false,"name":"Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.","description":"Although survival rates for patients with newly diagnosed multiple myeloma (NDMM) have improved over recent decades, multiple myeloma (MM) remains without a cure for most. There is increasing consensus that achievement of deep remissions, especially minimal residual disease negativity (MRD -), in frontline treatment is crucial and translates into improved survival. The standard of care (SOC) for NDMM consists at minimum of a triplet regimen of therapies, with or without an autologous stem cell transplant, or a doublet regimen for certain ineligible, particularly frail patients who may have specific limitations. Recently, anti-CD38 monoclonal antibodies (mAbs), such as daratumumab (Dara) or isatuximab (Isa), have been integrated into frontline SOC regimens. Seeking to further deepen and pro","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-02T20:38:50.957Z","creation":"2025-07-11T03:04:02.236Z"},"accession":"S-EPMC12031813","cross_references":{"pubmed":["39774926"],"doi":["10.1007/s00277-024-06143-7"]}}